ClinicalTrials.gg
SuspendedNCT06673095Updated Oct 20, 2026

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

An interventional study of Biospecimen Collection and Excision in Clinical Stage IA Cutaneous Melanoma AJCC v8 and Clinical Stage IB Cutaneous Melanoma AJCC v8, sponsored by OHSU Knight Cancer Institute. Suspended at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by OHSU Knight Cancer Institute · Not applicable, Interventional, and Treatment

How we know

Why this study was suspended
Pending coordinating center transition
Updated Oct 20, 2026Now SuspendedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Melanoma by OHSU Knight Cancer Institute — 2 open to participants now, 4 under way, none of them phase 3. Melanoma · OHSU Knight Cancer Institute.

Started
2024
with 1 other
No phase
6 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Melanoma by OHSU Knight Cancer Institute, this one is one of 2 that started in 2024, is one of 6 with no phase, and was the 9th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 11 studies in Melanoma by OHSU Knight Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Melanoma by OHSU Knight Cancer Institute, or all of them as a file.
02

Study summary

This clinical trial compares the effect of a narrow surgical excision (removal) to a wide excision for the treatment of adults with invasive cutaneous melanoma. Currently the standard of care is to take wide margins (boarder of healthy tissue surrounding the melanoma) when removing melanoma. Narrow margin excision removes a smaller amount of healthy tissue when surgically removing the melanoma. Narrow margin excision may be effective in removing the melanoma while also reducing surgical complications and improving quality of life for adults with invasive cutaneous melanoma.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare the 3-year local recurrence-free survival rates (RFS) in melanoma patients treated with narrow excision versus (vs) wide excision.

SECONDARY OBJECTIVES:

I. To measure the 3-, 5-year Regional (nodal) disease-free survival (DFS) in melanoma patients treated with active nodal surveillance.

II. To compare 5-year local recurrence-free survival in patients treated with narrow vs wide excision.

III. To compare 5-year Melanoma Specific Survival (MSS) in patients treated with narrow vs wide excision.

IV. To compare the quality of life in patients treated with narrow vs wide excision.

V. To compare surgical complication rates in patients treated with narrow vs wide excision.

VI. To compare the frequency of complex reconstruction in patients treated with narrow vs wide excision.

VII. To compare the final defect size in patients treated with narrow vs wide excision.

VIII. To compare the number of operative/procedure days required to achieve negative margins.

EXPLORATORY OBJECTIVE:

I. To measure the T- and B-cell repertoires in patients with melanoma over time.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo narrow margin excision on study. Patients may optionally undergo blood sample collection throughout the study.

ARM II: Patients undergo wide margin excision on study. Patients may optionally undergo blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 1 week, 3, 6, 12, 36, 48, and 60 months.

03

Conditions studied

  • Clinical Stage IA Cutaneous Melanoma AJCC v8
  • Clinical Stage IB Cutaneous Melanoma AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants or legally authorized representatives (LAR) must provide written before any study-specific procedures or interventions are performed
  • Age ≥ 18 years; all biological gender identities and racial/ethnic groups will be included
  • Participants must have confirmed primary cutaneous melanoma. Acral melanomas are eligible.
  • Participants must have one of the following:

    • American Joint Committee on Cancer (AJCC) 8th Ed clinical stage IA disease with Breslow thickness > 0.5 mm AND at least one high-risk feature (Mitotic rate ≥ 2/mm2, age ≤ 42, lymphovascular invasion, head/neck location)
    • AJCC 8th Ed Clinical Stage IB melanoma

      • If a melanoma is widely transected and the true Breslow depth is uncertain, then to be eligible for this trial, the melanoma must be re-biopsied to ascertain an accurate Breslow depth.
  • The index melanoma must be classified as low risk on the Merlin Assay (SkylineDx)
  • Study intervention (surgery) must be completed within 120 days of the original diagnostic
  • (ECOG) performance status ≤ 2 ( ≥ 50%)
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Participants with a history of infection are eligible
  • Participants can speak, read and write in English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Uncertain diagnosis of melanoma (i.e. severely dysplastic nevi, melanocytic lesion of unknown malignant potential, atypical intraepidermal melanocytic proliferations)
  • The patient has already undergone wide local excision at the site of the primary index lesion
  • The patient has a pure desmoplastic melanoma. A pure desmoplastic melanoma is defined as being > 90% desmoplastic type. Melanomas with \< 90% desmoplastic type may be included in this trial
  • Mucosal and ocular melanomas are also excluded, as these are approached differently for surgical excision
  • Physical, clinical, radiographic, or pathologic evidence of satellite, in-transit, regional, or distant melanoma
  • Participants with known or suspected cancer with regional or distant metastasis are excluded from this clinical trial because this trial is aimed at evaluating the control of localized disease
  • The patient has undergone surgery on a separate occasion to clear the lymph nodes of the probable draining lymphatic field, including a sentinel lymph node , of the index melanoma
  • Planned radiotherapy to the primary melanoma site after excision
  • Participant is unwilling or unable to comply with study procedures
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Arm I (narrow margin excision)

    Patients undergo narrow margin excision on study. Patients may optionally undergo blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Excision · Other: Survey Administration

  • Active comparator
    Arm II (wide margin excision)

    Patients undergo wide margin excision on study. Patients may optionally undergo blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Excision · Other: Survey Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureExcision

    Undergo narrow margin excision

    Also known as: Abscission, Extirpation, Surgical Removal

  • ProcedureExcision

    Undergo wide margin excision

    Also known as: Abscission, Extirpation, Surgical Removal

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Local recurrence rate

    Defined as average rate at which cancer returns to same location as the original tumor.

    Time frame: From randomization to end of year 3

Secondary outcomes

  1. Regional (nodal) disease-free survival

    Average number of participants who are experiencing regional disease-free survival at 3 and 5 years.

    Time frame: From randomization to end of year 5

  2. Local recurrence-free survival

    The average length of time (in months) from the date of randomization to local recurrence.

    Time frame: From randomization to end of year 5

  3. Melanoma-specific survival

    The average length of time (in months) from date of randomization to death.

    Time frame: From randomization to end of year 5

  4. Postoperative pain

    Measured by numeric rating scale (0-10).

    Time frame: Up to 30 days after surgery

  5. Quality of life

    Quality of life score as measured by either the Facial Appearance, Quality of Life, and Experience Questionnaire (FACE-Q) score in patients with melanoma on the face or the Functional Assessment of Cancer Therapy - Melanoma (FACT-M) score for patients with melanoma elsewhere on the body. FACT-M is a tool for measuring health-related quality of life in patients with melanoma. It has 51 items, Scores range from 0 to 120 with higher score indicating better quality of life (QOL). FACE-Q includes 5 independently functioning scales and 2 checklists that measure outcomes important to patients from their perspective.

    Time frame: Up to postoperative day 90

  6. Surgical complication rate

    Defined as the proportion of patients experiencing a surgical complication.

    Time frame: Up to postoperative day 90

  7. Frequency of complex reconstruction

    Defined as the proportion of patients receiving any flap or graft reconstruction.

    Time frame: Immediately after surgery

  8. Defect size

    The size of the defect is measured as the greatest dimension of the final wound multiplied by the dimension perpendicular to the greatest dimension.

    Time frame: Immediately after surgery

  9. Number of operative/procedure days

    Will compare the number of operative/procedure days required to achieve negative margins. Will be reported and compared separately (Mohs surgery, narrow excision with permanent sections, wide excision with permanent sections, and slow Mohs).

    Time frame: Up to postoperative day 90

07

Study locations

5 sites
  • University of California, Davis
    Davis, California 95817, United States
  • University of Kentucky/Markey Cancer Center
    Lexington, Kentucky 40536, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • OHSU Knight Cancer Institute
    Portland, Oregon 97239, United States
08

References and documents

Publications

  • Bichakjian CK, Swetter SM, Carroll BT, Vidal NY, Simons EA, Vetto JT, Yu WY. ICEMAN (Intelligent Choice of Excision Margin): A Randomized Controlled Trial of Adaptive Narrow Excision Versus Wide Excision for Adults with AJCC Stage I Cutaneous Melanoma. Ann Surg Oncol. 2025 Dec;32(13):9488-9490. doi: 10.1245/s10434-025-18282-w. Epub 2025 Sep 8. PubMed 40921901 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Nov 4, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended Pending coordinating center transition
changed Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Suspended
    Why stopped Pending coordinating center transition
    + 4 other changes: verification date, responsible party, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06673095
Responsible party
Cynthia Morris, Ph.D., M.P.H. (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Nov 4, 2024
Start date
Dec 11, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Cynthia Morris, Ph.D., M.P.H.
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion